EFFICACY, SAFETY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G IN ADULT PATIENTS WITH PRIMARY IMMUNODEFICIENCIES: PHASE 3 STUDY RESULTS

被引：0

作者：

Stein, Mark ^{[1
]}

Wasserman, Richard L. ^{[2
]}

Melamed, Isaac ^{[3
]}

Rubinstein, Arye ^{[4
,5
]}

Puck, Jennifer ^{[6
]}

Gupta, Sudhir ^{[7
]}

Engl, Werner ^{[8
]}

Leibl, Heinz ^{[8
]}

McCoy, Barbara ^{[8
]}

Yel, Leman ^{[9
]}

Schiff, Richard I. ^{[9
]}

机构：

[1] Allergy Associates Palm Beaches, North Palm Beach, FL USA

[2] DallasAllergyImmunol, Dallas, TX USA

[3] IMMUNOe Hlth Ctr, Centennial, CO USA

[4] Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Montefiore Hosp, Bronx, NY USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Univ Calif Irvine, Irvine, CA USA

[8] Baxter BioSci, Vienna, Austria

[9] Baxter BioSci, Westlake Village, CA USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2014年 / 34卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：727 / 727

页数：1

共 50 条

[41] POST-AUTHORIZATION SAFETY STUDY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
Rubinstein, A.
Bridges, T.
McNeil, D.
Tachdjian, R.
Wedner, H.
Wasserman, R.
Leibl, H.
Rabbat, C.
Honigberg, R.
Yel, L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S71 - S71
[42] REAL-WORLD USE OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IG) (IGHY; HYQVIA) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISORDERS (PIDD)
Rosenbach, Kevin P.
Hughes, Stephanie M.
Rozen, Leon
JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 271 - 272
[43] A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
Nagy, Andras
Duff, Kimberly
Bauer, Alexander
Okonneh, Fred
Rondon, Juan Carlos
Yel, Leman
Li, Zhaoyang
JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (01)
[44] A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
Andras Nagy
Kimberly Duff
Alexander Bauer
Fred Okonneh
Juan Carlos Rondon
Leman Yel
Zhaoyang Li
Journal of Clinical Immunology, 2024, 44
[45] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience
Francesca Angelotti
Riccardo Capecchi
Daiana Giannini
Ornella Mazzarella
Valeria Rocchi
Paola Migliorini
Clinical and Experimental Medicine, 2020, 20 : 387 - 392
[46] Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies
Gupta, Sudhir
Kobayashi, Roger
Melamed, Isaac
Rehman, Syed
Kobayashi, Ai
Mandujano, jose-Fernando
Geng, Bob
Ritchie, Bruce
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB76 - AB76
[47] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(R)) in immunodeficiency diseases: real-life data from a monocentric experience
Angelotti, Francesca
Capecchi, Riccardo
Giannini, Daiana
Mazzarella, Ornella
Rocchi, Valeria
Migliorini, Paola
CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 20 (03) : 387 - 392
[48] RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNO GLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PI): LONG TERM SAFETY, EFFICACY, AND TOLERABILITY.
Wasserman, R. L.
Stein, M.
Melamed, I.
Kobrynski, L.
Grant, J. A.
Gupta, S.
Engl, W.
Leibl, H.
Yel, L.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A89 - A89
[49] Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)
Wasserman, R. L.
Melamed, I.
Stein, M.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB15 - AB15
[50] Efficacy, Tolerability and Safety of Cutaquig®, a New Subcutaneous Human Immunglobulin 16.5% in Adult Patients with Primary Immunodeficiencies
Latysheva, E.
Rodina, Y.
Sizyakina, L.
Totolian, A.
Tuzankina, I
JOURNAL OF CLINICAL IMMUNOLOGY, 2019, 39 : S64 - S65

← 1 2 3 4 5 →